Biohaven’s Opakalim Data Shows 3-Fold Reduction in Seizure Events and Low Side Effects in Epilepsy Trials
Clinical Trials Demonstrate Significant Benefits for Epilepsy Patients
Biohaven (NYSE: BHVN) unveiled new clinical data highlighting the efficacy and tolerability of its selective Kv7.2/7.3 channel activator, Opakalim, in epilepsy. Among the main findings, patients with idiopathic generalized epilepsy (IGE) treated with Opakalim experienced a median time to second seizure that was 141 days—three times longer than the 47 days seen in the placebo group.
Efficacy Extends Across Multiple Forms of Epilepsy
Opakalim’s benefit was consistent in both generalized and focal epilepsy:
- In IGE: 33% of patients on Opakalim completed the entire 24-week trial without a second seizure, while none did so on placebo.
- Focal epilepsy (open-label extension): 54% of patients achieved at least a 50% reduction in seizure frequency over any six-month period compared to their baseline.
| Study Group | Key Efficacy Outcome | Placebo/Comparator | Opakalim (75 mg) |
|---|---|---|---|
| IGE (Median time to 2nd seizure) | Days to event | 47 | 141 |
| IGE (Completed 24 weeks w/o 2nd seizure) | Percentage | 0% | 33% |
| Focal Epilepsy (=50% reduction in seizure frequency) | Percentage | - | 54% |
Tolerability Profile Sets Opakalim Apart
One of the most striking aspects of Opakalim’s data is its safety profile. Across more than 1,000 subjects, the drug showed low rates of central nervous system (CNS) adverse events—contrasting sharply with competitors where side effects such as somnolence, dizziness, fatigue, and memory problems often occur in double-digit percentages.
| Adverse Event | Opakalim (Focal Epilepsy OLE Study) | Leading Kv7 Activator (Comparator Data) |
|---|---|---|
| Dizziness | 5% | 25% |
| Somnolence | =5% | 17% |
| Memory Impairment | =5% | 11% |
| Falls | - | 15% |
This cleaner profile is particularly relevant for patients sensitive to neurological side effects—a major barrier in epilepsy therapy adherence and quality of life. Notably, Opakalim requires no gradual dose titration and is taken once daily, making it an attractive candidate for broad clinical use.
Pediatric Compassionate Use Case Shows Promise
Clinical stability was also observed in a pediatric case of KCNQ2-Developmental and Epileptic Encephalopathy. The 9-year-old patient demonstrated a 50% reduction in overnight seizure frequency after six months on Opakalim, despite prior treatment failures on multiple therapies—including a first-generation Kv7 activator.
Pivotal Data Expected in 2026
Biohaven is on track to deliver top-line results from its Phase 2/3 trials in refractory focal epilepsy in the second half of 2026. Early completion and rollover rates in these studies (both at 95%) reflect significant confidence from participants and investigators in the drug’s effect and safety thus far.
Key Takeaways for Investors and Clinicians
- Opakalim meaningfully extends seizure-free time in IGE by 3-fold over placebo and halves seizure frequency for over half of refractory focal epilepsy patients.
- The drug’s tolerability is markedly differentiated from existing ASM options—potentially addressing a historic gap in therapy for people with epilepsy.
- With pivotal data expected by late 2026, Opakalim could reshape the therapeutic landscape for epilepsy if larger studies reaffirm these patterns.
For investors or healthcare professionals seeking safer, more effective epilepsy solutions, Opakalim’s emerging profile and pending late-stage results warrant close attention as 2026 approaches.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI